Maxim Group analyst Anthony Vendetti reiterated a Buy rating on Electrocore (ECOR – Research Report) yesterday and set a price target of $15.00. The company’s shares closed yesterday at $5.70.
Vendetti covers the Healthcare sector, focusing on stocks such as Cutera, Sensus Healthcare, and Venus Concept. According to TipRanks, Vendetti has an average return of -1.3% and a 32.33% success rate on recommended stocks.
Electrocore has an analyst consensus of Strong Buy, with a price target consensus of $14.58, which is a 155.79% upside from current levels. In a report released yesterday, H.C. Wainwright also maintained a Buy rating on the stock with a $10.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
ECOR market cap is currently $27.07M and has a P/E ratio of -1.20.
Based on the recent corporate insider activity of 30 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ECOR in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
electroCore, Inc. is a commercial-stage bio-electronic medicine company, with a platform non-invasive vagus nerve stimulation therapy focuses on neurology and rheumatology. The company’s therapy, gammaCore, has pharmacologic effects on the peripheral and central nervous systems, which modulate neurotransmitters and immune function. It focuses on acute treatment of migraine and episodic cluster headache. The company was founded by Joseph P. Errico, Steve Mendez, Peter S. Staats and Thomas J. Errico in September 2005 and is headquartered in Morris Plains, NJ.
Read More on ECOR:
- electroCore reports Q1 EPS ($1.24), consensus ($1.00)
- electroCore Announces First Quarter 2023 Financial Results
- electroCore to Participate at Annual Aegis Virtual Conference
- National Institutes of Health Awards Grant for Pivotal Clinical Trial of gammaCore™ (nVNS) in Patients with Opioid Use Disorders
- electroCore announces NIDA awarded Emory University, Georgia Institute a grant
